Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.

You may also be interested in...



Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.

Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance

FDA’s response to new data on Remoxy could serve as a model for how the agency expects to deal with the abuse-deterrent formulations it is encouraging for oxycodone and other opioids.

Does Mandatory Opioid Prescriber Education Go Far Enough? Congress Might Say No

Congress and FDA already are sparring over the drug companies’ mandate to pay for the prescriber education included in the national prescription drug abuse plan.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel